Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases?

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Bertin, Daniel ^a,b   Stephan, Delphine ^a   Khrestchatisky, Michel ^a   Desplat Jégo, Sophie ^a,b  

^a Mediterranée University   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Auto immunity; Biomarker; Disease monitoring; Serum levels; TWEAK; Urinary levels

Indexed keywords

BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR; TWEAK; UNCLASSIFIED DRUG;

AUTOIMMUNE CHRONIC INFLAMMATORY DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; MONITORING; MONOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SAFETY; SHORT SURVEY;

EID: 84892185663     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00489     Document Type: Short Survey

References (31)

1. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009) 33(3-4):197-207. doi:10.1016/j.jaut.2009.09.008
2. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 40(1):1-16. doi:10.1016/j.cyto.2007.09.007
3. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther (2013) 35(8):1137-49. doi:10.1016/j.clinthera.2013.06.008
4. ATLAS. Anti-TWEAK in Lupus Nephritis Patients. Clinical Trials.gov (2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01499355?term=BIIB023&rank=3
5. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 11(5):R143. doi:10.1186/ar2816
6. El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol (2011) 31(5):848-56. doi:10.1007/s10875-011-9555-1
7. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a novel arthritogenic mediator. J Immunol (2006) 177(4):2610-20.
8. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol (2006) 177(9):6433-9.
9. Park M-C, Chung SJ, Jung S-J, Park Y-B, Lee S-K. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol (2008) 37(3):173-8. doi:10.1080/03009740801898608
10. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol (2009) 36(8):1657-62. doi:10.3899/jrheum.081310
11. Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol (2008) 67(12):1137-48. doi:10.1097/NEN.0b013e31818dab90
12. Van Kuijk AWR, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis (2010) 69(1):301-4. doi:10.1136/ard.2008.090548
13. Desplat-Jégo S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol (2002) 133(1-2):116-23. doi:10.1016/S0165-5728(02)00368-5
14. Desplat-Jégo S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol (2005) 117(1):15-23. doi:10.1016/j.clim.2005.06.005
15. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med (2000) 192(9):1373-80. doi:10.1084/jem.192.9.1373
16. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol (2000) 164(6):2897-904.
17. Desplat-Jégo S, Feuillet L, Creidy R, Malikova I, Rance R, Khrestchatisky M, et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol (2009) 85(1):132-5. doi:10.1189/jlb.0608347
18. Dharmapatni AASSK, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 13(2):R51. doi:10.1186/ar3294
19. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun (2006) 27(4):242-50. doi:10.1016/j.jaut.2006.12.003
20. Liu Z-C, Zhou Q-L, Li X-Z, Yang J-H, Ao X, Veeraragoo P, et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine (2011) 53(3):295-300. doi:10.1016/j.cyto.2010.11.012
21. Bielecki M, Kowal K, Lapinska A, Chwiecko J, Skowronski J, Sierakowski S, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol (2009) 47(3):465-9. doi:10.2478/v10042-009-0103-2
22. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 207(1):103-10. doi:10.1016/j.atherosclerosis.2009.04.033
23. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 178(12):8183-94.
24. Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, et al. Studies of binding of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem (2012) 287(1):484-95. doi:10.1074/jbc.M111.287656
25. Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, et al. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther (2013) 15(3):R69. doi:10.1186/ar4246
26. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, et al. Soluble TWEAK plamsa levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 4(11):1716-23. doi:10.2215/CJN.02760409
27. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis (2010) 211:322-6. doi:10.1016/j.atherosclerosis.2010.02.016
28. Xia L, Shen H, Xiao W, Lu J. Increased serum TWEAK levels in psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine (2011) 53(3):289-91. doi:10.1016/j.cyto.2010.12.003
29. Turmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol (2013) 14:144. doi:10.1186/1471-2369-14-144
30. Llaurado G, Gonzalez-Clemente JM, Maymo-Massip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors: a case-control study. PLoS One (2012) 7 (8):e43919. doi:10.1371/journal.pone.0043919
31. Lammens A, Baehner M, Kohnert U, Niewoehner J, von Proff L, Schraeml M, et al. Crystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding. PLoS One (2013) 8(5):e62697. doi:10.1371/journal.pone.0062697